Navigation Links
Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
Date:10/14/2008

best-in-class product with favorable hemodynamic and renal activity," said Peter Strumph, Chief Executive Officer of Nile. "We believe that the results from this patient population will be predictive of activity in our upcoming Phase 2b study in acute heart failure patients. We look forward to announcing the full results from this Phase 2a study, as well as results from the ongoing phase 1b study in stable heart failure patients."

Information regarding this study is available at the U.S. government's clinical trials database at http://www.clinicaltrials.gov.

About Heart Failure

Heart failure (HF) is a chronic condition in which the heart cannot effectively pump enough blood to the body's other organs, either as a result of impaired contractility (systolic heart failure) or impaired relaxation and ventricular filling (diastolic heart failure). HF is a major and growing public health problem affecting 5.3 million Americans, with over 650,000 new cases diagnosed every year. The annual mortality rate for heart failure is 19%. Treatment of Heart Failure generates annual costs of approximately $35 billion, of which approximately $3 billion is spent on drugs and $19 billion is spent in the acute hospital setting. Heart Failure patients frequently suffer episodes of acute decompensated heart failure (ADHF) which require hospitalization. For Americans over 65 years of age, ADHF is the most frequent cause of hospital admission. In recent years, 2.4 million patients in the US were hospitalized with a primary or secondary discharge code of ADHF with an average hospital stay of 4.3 days.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of ADHF. CD-NP was rationally designed by scientists at the Mayo Clinic's Cardiorenal Research Labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable p
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider of ... today announced its participation in the 2014 Big Data ... solutions provide semantic linkage and meaning to Big Data ... manage diverse data. Ben Szekely, vice president and founding ... “life sciences data lake” and an approach for collecting ...
(Date:10/1/2014)... Greifensee, Switzerland (PRWEB) October 01, 2014 ... influence the quality of the final product. However, ... most regulated, regulatory frameworks such as Good Manufacturing ... is the responsibility of the manufacturer to interpret ... ensure consistent weighing performance quality. METTLER TOLEDO experts ...
(Date:10/1/2014)... 30, 2014 The participants committed to ... to spending their own time adjusting, tweaking and testing ... designs were ready for judging. , “I enjoyed being ... thought leader. “The entries showed a commendable range ... characteristics of the print medium and the creativity of ...
(Date:10/1/2014)... Award winning unified communications (UC) ... new-hosted collaboration bundles that combine next generation communication ... experiences for low, flat rate fees. With ... have optimized solutions to meet their technology needs. ... only minutes (1K, 5K, 10K increments) or audio ...
Breaking Biology Technology:Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2SoundConnect Launches New Audio, Web and Video Bundles 2
... Oct. 16 Compendia Bioscience, Inc.,today announced ... Premium Edition, a high-value product extension of ... Oncomine Research,Premium Edition includes custom gene filters, ... support for Oncomine Concepts Map,including the ability ...
... DRRX ) announced today that it will be hosting ... at 12:00 p.m. Eastern Time. A live audio,webcast of ... and will,be available by accessing DURECT,s homepage at ... to participate during the,live webcast, the call will be ...
... will receive milestones and ... by Altair - Altair to conduct clinical development ... FRANCISCO, Oct. 16 ,Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Inc., a new venture,capital-funded biotechnology company, has been created to ...
Cached Biology Technology:Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 2Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 3Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 4Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions 5
(Date:10/2/2014)... 2014 CARTES ... identification and mobility which is being held at ... 6 November 2014, is proud to announce the ... agency FABERNOVEL.        (Logo: http://photos.prnewswire.com/prnh/20140526/689195) ... to support innovative businesses from the digital security ...
(Date:10/2/2014)... 2014 CARTES SECURE CONNEXIONS 2014 Conference: ... Sector CARTES SECURE CONNEXIONS 2014 is being held ... 6 November 2014. This 29 th  international meeting for ... mobility, will bring together the global community of a ... programme of conferences will set the pace for the ...
(Date:10/1/2014)... inheritance, showing for the first time that offspring can ... at least., This confronting idea, known as telegony, dates ... the early 20th Century with the advent of genetics., ... Crean, Professor Russell Bonduriansky and Dr Anna Kopps manipulated ... They found that the size of the young was ...
Breaking Biology News(10 mins):CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 2CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 3CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 4CARTES SECURE CONNEXIONS 2014 Launches the "Startup Challenge" to Support the Future Champions of Innovation 5CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 2CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 3CARTES SECURE CONNEXIONS - Conferences & Speakers 2014 4Semen secrets: How a previous sexual partner can influence another male's offspring 2
... multiple languages, cultures, races and religions, but among this diversity ... more united through our ears. In fact Mihailo Antovic, ... proposes that our musical conceptualization brings together a world of ... of distinct ethnic backgrounds and languages in his home of ...
... registration and abstract submission is now open at ... to be held in the Middle-East and Africa region. ... part of a new series of ,IOF Regionals, around ... energize research efforts in the region while offering advanced ...
... A drug already approved for people with cancer ... form of dementia, UT Southwestern Medical Center researchers report. ... a first-generation drug for the prevention and treatment of ... for which there is no treatment," said Dr. Joachim ...
Cached Biology News:1 world, 1 sound 21 world, 1 sound 3Cancer drug holds promise as first treatment for common, inherited dementia 2